FDA plans to reduce drug development costs

Janet Woodcock, the recently reappointed head of the FDA Centre for Drug Evaluation and Research said the FDA would unveil proposals this autumn on reducing drug development costs by standardising the format and content of clinical trial data.
Financial Times